Core Insights - The report highlights the rapid growth and potential of the tumor immune cell therapy industry, which is seen as a key breakthrough in cancer treatment, driven by increasing global cancer challenges and limitations of traditional therapies [3][8][10] - The global market for tumor immune cell therapy is projected to reach $84.9 billion by 2030, with China expected to reach 69.5 billion yuan, reflecting a compound annual growth rate (CAGR) of 177.4% from 2017 to 2023 [3][9][10] Disease Challenges - The global cancer burden is escalating, with over 20 million new cases and nearly 10 million deaths expected in 2024, highlighting the urgent need for more effective and safer treatment options beyond traditional methods [3][8] Technology Principles - Tumor immune cell therapy enhances the body's immune response by modifying immune cells outside the body and reintroducing them to target cancer cells, utilizing technologies such as CAR-T, TCR-T, and NK cell therapies [3][8][9] Market Scale - The industry has entered a high-growth phase since the approval of the first CAR-T cell therapy product in 2017, with significant market expansion anticipated as more therapies receive approval [9][10] Industry Collaboration - There is a collaborative effort among government, enterprises, and research institutions to support the development of the tumor immune cell therapy industry, including policy initiatives to streamline product evaluation and enhance research and development [10]